- Policy
- Daewoong joins in competition in the Forxiga generic market
- by Lee, Tak-Sun Mar 26, 2024 06:30am
- Daewoong Pharmaceutical, which had been in charge of the domestic sales and marketing of the original SGLT-2 diabetes drug ‘Forxiga (propanediol hydrate),’ is belatedly entering the generic market through a transfer and acquisition deal. Daewoong had sold Forxiga until January this year. It is analyzed that Daewoong also entered the gen
- Policy
- Pfizer tops global mkt…Samsung Biologics tops Korean mkt
- by Lee, Hye-Kyung Mar 26, 2024 06:30am
- In 2022, global pharmaceutical giant Pfizer and Korean pharmaceutical giant Samsung Biologics took the top spots in terms of sales, earning KRW 91 billion and KRW 2.437 trillion, respectively. in 2022, according to a new report released by the Korea Health Industry Development Institute, According to the '2023 Health Industry Statistics' rec
- Policy
- Sotyktu, Livtencity to be reimb from April
- by Lee, Jeong-Hwan Mar 25, 2024 05:59am
- Sotyktu for plaque psoriasis and Livtencity 200 mg for cytomegalovirus (CMV) infection will be newly listed for reimbursement from the 1st of next month. GLP-1 receptor agonists (GLP-1 RAs, single-agent therapy, and combination therapy) will be reimbursed for use in combination with basal insulin therapy when a patient’s HbA1c level is 7
- InterView
- ‘New head, new drugs…Bayer’s transition has just begun'
- by Eo, Yun-Ho Mar 25, 2024 05:59am
- Everyone gets stuck at some point. The difference is in how quickly you resolve the situation and carry on. The multinational pharmaceutical giant Bayer Korea was certainly ‘stuck’ at one point. Although the company had released and successfully sold liver cancer treatments ‘Nexavar’ and ‘Stivarga,’ the anticoagulant ‘Xarelto,’ a
- Policy
- Expanded ‘pre-notification for change approval’
- by Lee, Hye-Kyung Mar 25, 2024 05:59am
- The pilot system for ‘pre-notification for pharmaceutical change approval,’ which allows companies to predict the schedule of post-approval changes, will now applied to pharmaceuticals required for reporting production, imports, and supply disruptions. Since December 18th of last year, the Ministry of Food and Drug Safety (MFDS) has been i
- Policy
- Samsung Bioepis’s Soliris biosimilar is introduced
- by Lee, Tak-Sun Mar 25, 2024 05:59am
- The cost of Soliris (eculizumab), a drug known for its high price, is expected to drop significantly with the introduction of its biosimilar. The original Soliris will also cut its price by 30% in line with the expansion of its reimbursement benefit to cover neuromyelitis optica, to compete with its biosimilars. According to industry s
- Company
- K-bio, R&D global competitiveness will be put to the test
- by Son, Hyung-Min Mar 22, 2024 06:09am
- The Korean pharmaceutical industry will showcase its new candidate products entering late-stage clinical trials or aiming to export technology on platforms, testing their global competitiveness. The spotlight is on these new candidate products, particularly the trending bispecific antibodies and antibody-drug conjugate (ADC), to identify w
- Company
- Lotte Biologics’ sales amount to KRW 228.6 billion
- by Kim, Jin-Gu Mar 22, 2024 06:09am
- Lotte Biologics recorded sales of KRW 228.6 billion last year. As the Syracuse manufacturing plant in the United States went into full-scale production, sales of KRW 83.1 billion in the first half of the year expanded to KRW 145.6 billion in the second half of the year. The analysis indicates that Lotte Biologics’ Contract development
- Policy
- Economic benefits paid to doctors to be publicly disclosed
- by Lee, Jeong-Hwan Mar 22, 2024 06:08am
- On the 21st, the government announced the guidelines for the public disclosure of expenditure reports on the legitimate financial benefits paid by pharmaceutical and medical device companies to doctors and pharmacists that will be disclosed in December. The guidelines stipulate the detailed schedule, content, and method for disclosure of
- Company
- Antihistamine sales benefit from end of pandemic and endemic
- by Son, Hyung-Min Mar 22, 2024 06:06am
- Last year, sales of major antihistamines showed a clear recovery, exceeding the level it had made before the pandemic. Sales of antihistamines had plummeted in 2020 and 2021 during the COVID-19 pandemic. The analysis is that the increase in sales is likely due to the rise in allergy patients with the lifted mask mandates and the increase in outd
